Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Penno, G.
Right arrow Articles by Fuller, J. H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Penno, G.
Right arrow Articles by Fuller, J. H.
Social Bookmarking
Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 47, Issue 9 1507-1511, Copyright © 1998 by American Diabetes Association

ARTICLES

Effect of angiotensin-converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID Randomized Controlled Trial. EURODIAB Controlled Trial of Lisinopril in IDDM

G Penno, N Chaturvedi, PJ Talmud, P Cotroneo, A Manto, M Nannipieri, LA Luong and JH Fuller
Cattedra di Malattie Metaboliche e del Ricambio, Presidio Ospedaliero di Cisanello Diabetologia, Pisa, Italy.

We examined whether the ACE gene insertion/deletion (I/D) polymorphism modulates renal disease progression in IDDM and how ACE inhibitors influence this relationship. The EURODIAB Controlled Trial of Lisinopril in IDDM is a multicenter randomized placebo-controlled trial in 530 nonhypertensive, mainly normoalbuminuric IDDM patients aged 20-59 years. Albumin excretion rate (AER) was measured every 6 months for 2 years. Genotype distribution was 15% II, 58% ID, and 27% DD. Between genotypes, there were no differences in baseline characteristics or in changes in blood pressure and glycemic control throughout the trial. There was a significant interaction between the II and DD genotype groups and treatment on change in AER (P = 0.05). Patients with the II genotype showed the fastest rate of AER progression on placebo but had an enhanced response to lisinopril. AER at 2 years (adjusted for baseline AER) was 51.3% lower on lisinopril than placebo in the II genotype patients (95% CI, 15.7 to 71.8; P = 0.01), 14.8% in the ID group (-7.8 to 32.7; P = 0.2), and 7.7% in the DD group (-36.6 to 37.6; P = 0.7). Absolute differences in AER between placebo and lisinopril at 2 years were 8.1, 1.7, and 0.8 microg/min in the II, ID, and DD groups, respectively. The significant beneficial effect of lisinopril on AER in the II group persisted when adjusted for center, blood pressure, and glycemic control, and also for diastolic blood pressure at 1 month into the study. Progression from normoalbuminuria to microalbuminuria (lisinopril versus placebo) was 0.27 (0.03-2.26; P = 0.2) in the II group, and 1.30 (0.33-5.17; P = 0.7) in the DD group (P = 0.6 for interaction). Knowledge of ACE genotype may be of value in determining the likely impact of ACE inhibitor treatment.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 DiabetesHome page
L. Weekers, B. Bouhanick, S. Hadjadj, Y. Gallois, R. Roussel, F. Pean, A. Ankotche, G. Chatellier, F. Alhenc-Gelas, P. J. Lefebvre, et al.
Modulation of the Renal Response to ACE Inhibition by ACE Insertion/Deletion Polymorphism During Hyperglycemia in Normotensive, Normoalbuminuric Type 1 Diabetic Patients
Diabetes, October 1, 2005; 54(10): 2961 - 2967.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
M. Ravera, E. Ratto, S. Vettoretti, D. Parodi, and G. Deferrari
Prevention and Treatment of Diabetic Nephropathy: The Program for Irbesartan Mortality and Morbidity Evaluation
J. Am. Soc. Nephrol., March 1, 2005; 16(3_suppl_1): S48 - S52.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
G. Deferrari, M. Ravera, V. Berruti, G. Leoncini, and L. Deferrari
Optimizing Therapy in the Diabetic Patient with Renal Disease: Antihypertensive Treatment
J. Am. Soc. Nephrol., January 1, 2004; 15(90010): S6 - 11.
[Abstract] [Full Text]

Home page
 J. Med. Genet.Home page
I Narita, S Goto, N Saito, J Song, K Omori, D Kondo, M Sakatsume, and F Gejyo
Renoprotective efficacy of renin-angiotensin inhibitors in IgA nephropathy is influenced by ACE A2350G polymorphism
J. Med. Genet., December 1, 2003; 40(12): e130 - 130.
[Full Text]

Home page
 NEJMHome page
E. G. Nabel
Cardiovascular Disease
N. Engl. J. Med., July 3, 2003; 349(1): 60 - 72.
[Full Text] [PDF]

Home page
 Arch Intern MedHome page
H. T. Yu
Progression of Chronic Renal Failure
Arch Intern Med, June 23, 2003; 163(12): 1417 - 1429.
[Abstract] [Full Text] [PDF]

Home page
 Diabetes CareHome page
S. Andersen, L. Tarnow, F. Cambien, P. Rossing, T. R. Juhl, J. Deinum, and H.-H. Parving
Long-Term Renoprotective Effects of Losartan in Diabetic Nephropathy: Interaction with ACE insertion/deletion genotype?
Diabetes Care, May 1, 2003; 26(5): 1501 - 1506.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
W E Evans
Pharmacogenomics: marshalling the human genome to individualise drug therapy
Gut, May 1, 2003; 52(90002): ii10 - 18.
[Abstract] [Full Text]

Home page
 DiabetesHome page
T. Abiko, A. Abiko, A. C. Clermont, B. Shoelson, N. Horio, J. Takahashi, A. P. Adamis, G. L. King, and S.-E. Bursell
Characterization of Retinal Leukostasis and Hemodynamics in Insulin Resistance and Diabetes: Role of Oxidants and Protein Kinase-C Activation
Diabetes, March 1, 2003; 52(3): 829 - 837.
[Abstract] [Full Text] [PDF]

Home page
 NEJMHome page
W. E. Evans and H. L. McLeod
Pharmacogenomics -- Drug Disposition, Drug Targets, and Side Effects
N. Engl. J. Med., February 6, 2003; 348(6): 538 - 549.
[Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
G. Deferrari, M. Ravera, L. Deferrari, S. Vettoretti, E. Ratto, and D. Parodi
Renal and Cardiovascular Protection in Type 2 Diabetes Mellitus: Angiotensin II Receptor Blockers
J. Am. Soc. Nephrol., November 1, 2002; 13(90003): S224 - 229.
[Abstract] [Full Text]

Home page
 Diabetes CareHome page
S. Fava, J. Azzopardi, S. Ellard, and A. T. Hattersley
ACE Gene Polymorphism as a Prognostic Indicator in Patients With Type 2 Diabetes and Established Renal Disease
Diabetes Care, December 1, 2001; 24(12): 2115 - 2120.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
S. HADJADJ, R. BELLOUM, B. BOUHANICK, Y. GALLOIS, G. GUILLOTEAU, G. CHATELLIER, F. ALHENC-GELAS, and M. MARRE
Prognostic Value of Angiotensin-I Converting Enzyme I/D Polymorphism for Nephropathy in Type 1 Diabetes Mellitus: A Prospective Study
J. Am. Soc. Nephrol., March 1, 2001; 12(3): 541 - 549.
[Abstract] [Full Text]

Home page
 Nephrol Dial TransplantHome page
S.-K. Ha, S. Yong Lee, H. Su Park, J. Ho Shin, S. Jung Kim, D. Hun Kim, K. Rae Kim, H. Yung Lee, and D. Suk Han
ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect of ACE inhibitors in patients with proteinuric non-insulin-dependent diabetes mellitus
Nephrol. Dial. Transplant., October 1, 2000; 15(10): 1617 - 1623.
[Abstract] [Full Text] [PDF]

Home page
 J. Am. Soc. Nephrol.Home page
J. C. POPE IV, J. W. BROCK III, M. C. ADAMS, F. D. STEPHENS, and I. ICHIKAWA
How They Begin and How They End: Classic and New Theories for theDevelopment and Deterioration of Congenital Anomalies of the Kidney andUrinary Tract, CAKUT
J. Am. Soc. Nephrol., September 1, 1999; 10(9): 2018 - 2028.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1998 by the American Diabetes Association.